Detalles de la búsqueda
1.
Anti-KIT monoclonal antibody CDX-0159 induces profound and durable mast cell suppression in a healthy volunteer study.
Allergy;
77(8): 2393-2403, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35184297
2.
Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer.
Cancers (Basel);
14(10)2022 May 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35625959
3.
Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients.
Clin Cancer Res;
25(19): 5752-5758, 2019 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31308059
4.
Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants.
Clin Cancer Res;
13(11): 3363-9, 2007 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-17545544
5.
High-throughput mass spectrometry screening for inhibitors of phosphatidylserine decarboxylase.
J Biomol Screen;
12(5): 628-34, 2007 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-17478478
6.
KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells.
Clin Cancer Res;
23(10): 2565-2574, 2017 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27815356
7.
Anti-KIT Monoclonal Antibody Treatment Enhances the Antitumor Activity of Immune Checkpoint Inhibitors by Reversing Tumor-Induced Immunosuppression.
Mol Cancer Ther;
16(4): 671-680, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28138031
8.
Targeting KIT on innate immune cells to enhance the antitumor activity of checkpoint inhibitors.
Immunotherapy;
8(7): 767-74, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-27349976
9.
Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.
Clin Cancer Res;
22(12): 2897-907, 2016 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26831715
10.
Emerging Receptor Tyrosine Kinase Drug Targets: Implications for Antibody-Based Therapies for Oncology and Immunologic Disorders.
Crit Rev Oncog;
20(5-6): 485-508, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-27279243
11.
First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies.
Clin Cancer Res;
19(4): 909-19, 2013 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-23403628
Resultados
1 -
11
de 11
1
Próxima >
>>